curasan AG

euro adhoc: quarterly or semiannual financial statement
curasan: First quarterly break-even result

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- quaterly report 25.04.2008 Kleinostheim, 25 April 2008 - curasan AG (ISIN: DE 000 549 453 8) has succeeded in increasing its revenues of Q1/2008 by 13% compared to Q1/2007 from 2.6 million Euro to 2.9 million Euro. Due to its concurrent cost reduction the company achieved a break-even in the quarterly revenue result for the first time. The full Q1/2008 report will be published on May 13, 2008. About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS® implant system, the company´s sales is focusing more prominently on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. Please visit curasan´s corporate website at end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: curasan AG Im Internet recherchierbar: Further inquiry note: Dr. Erwin Amashaufer, curasan AG, Tel. +49 6027/46 86-465, email: Branche: Biotechnology ISIN: DE0005494538 WKN: 549453 Index: CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Hamburg / free trade Börse Stuttgart / free trade Börse Düsseldorf / free trade Börse Hannover / free trade Börse München / free trade

Das könnte Sie auch interessieren: